Mirati Therapeutics (NASDAQ:MRTX):
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock.
The company is so far trading up from yesterday’s close of 14.05.
Mirati Therapeutics, Inc., launched on April 29, 2013, is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Business’s clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. Mocetinostat has completed approximately 10 clinical trials in over 400 patients with a range of hematologic malignancies and solid tumors..
Mirati Therapeutics currently has a P/E ratio of N/A and the market value is 355.48M. As of the latest earnings report the EPS was $-3.11 with 25.30M shares now outstanding.
Short traders are more bearish on shares of Mirati Therapeutics lately if you take note of the increase in short interest. The firm realized a rise in short interest from September 29, 2017 to October 13, 2017 of 23.31%. Short shares grew 236,350 over that period. The days to cover increased to 2.0 and the short interest percentage is 0.05% as of October 13.
Wall Street analysts have released ratings on the company. November 7 investment analysts at HC Wainwright reiterated a “Buy” rating on the stock. On October 12 HC Wainwright made no change to the company rating of “Buy” with a current price target of $20.00.
October 12 investment analysts at SunTrust Banks kept the stock rating at “Buy” targeting a price of $13.00. October 2 investment analysts at SunTrust Banks left the stock rating at “Buy” projecting a price of $13.00.
Equity analyst Cann updated coverage of MRTX by announcing an initial rating of “Outperform”. CIBC released research on MRTX giving it an initial rating of “Outperform”.